Article
Cardiac & Cardiovascular Systems
Harmony R. Reynolds, Michael H. Picard, John A. Spertus, Jesus Peteiro, Jose Luis Lopez Sendon, Roxy Senior, Mohammad C. El-Hajjar, Jelena Celutkiene, Michael D. Shapiro, Patricia A. Pellikka, Dennis F. Kunichoff, Rebecca Anthopolos, Khaled Alfakih, Khaled Abdul-Nour, Michel Khouri, Leonid Bershtein, Mark De Belder, Kian Keong Poh, John F. Beltrame, James K. Min, Jerome L. Fleg, Yi Li, David J. Maron, Judith S. Hochman
Summary: Improvement in ischemia and angina were common in patients with ischemia with no obstructive coronary artery disease (INOCA), but they were not significantly correlated. The pathophysiology of INOCA is complex and angina is multifactorial in nature.
Review
Cardiac & Cardiovascular Systems
Randall P. Sharp, Edna Patatanian, Riaz Sirajuddin
Summary: CMD is a cardiovascular disorder with treatment mainly focused on anti-ischemic drugs, where ranolazine may benefit some patients. However, larger and longer studies are needed to verify the effectiveness of ranolazine in treating CMD.
AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS
(2021)
Article
Cardiac & Cardiovascular Systems
Alessia Argiro, Mattia Zampieri, Lorenzo-Lupo Dei, Cecilia Ferrantini, Alberto Marchi, Alessia Tomberli, Katia Baldini, Francesco Cappelli, Silvia Favilli, Silvia Passantino, Chiara Zocchi, Luigi Tassetti, Martina Gabriele, Niccolo Maurizi, Niccolo Marchionni, Raffaele Coppini, Iacopo Olivotto
Summary: This study assessed the efficacy and safety of ranolazine in real-world patients with hypertrophic cardiomyopathy (HCM). The results showed that ranolazine had a certain therapeutic effect in relieving angina and reducing the burden of ventricular arrhythmias. However, no symptomatic improvement could be observed in patients with heart failure associated with severe diastolic dysfunction.
INTERNATIONAL JOURNAL OF CARDIOLOGY
(2023)
Article
Pharmacology & Pharmacy
Abdullah Kaplan, Ghadir Amin, Emna Abidi, Raffaele Altara, George W. Booz, Fouad A. Zouein
Summary: Ranolazine is an antianginal drug that acts through inhibiting the late sodium current in the heart. It has been extensively studied in experimental and clinical studies related to heart failure, as it inhibits various underlying mechanisms of cardiac remodeling.
EUROPEAN JOURNAL OF PHARMACOLOGY
(2022)
Article
Cardiac & Cardiovascular Systems
Timothy D. Henry, C. Noel Bairey Merz, Janet Wei, Michel T. Corban, Odayme Quesada, Sandy Joung, Christine L. Kotynski, Jian Wang, Michelle Lewis, Ann M. Schumacher, Ronnda L. Bartel, Hiroshi Takagi, Vishal Shah, Anna Lee, William K. Sietsema, Douglas W. Losordo, Amir Lerman
Summary: This study evaluated the safety and efficacy of intracoronary CD34+ cell therapy in patients with coronary microvascular dysfunction. The results showed that patients receiving CD34+ cell therapy had improved coronary flow reserve, reduced angina symptoms, and improved quality of life after 6 months of treatment. This study supports the potential therapeutic role of CD34+ cells in patients with microvascular angina.
CIRCULATION-CARDIOVASCULAR INTERVENTIONS
(2022)
Article
Medicine, General & Internal
Andrea Frustaci, Rosario Cianci, Romina Verardo, Bruna Cerbelli, Maria Cecilia D'Asdia, Alessandro De Luca
Summary: This study described a new genetic microvascular obstructive disease causing progressive hypo-perfusion of the human brain, heart, and kidney.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Pharmacology & Pharmacy
Hyounggyoon Yoo, Sang Won Lee, Deok Yong Yoon, Seo Hyun Yoon, Joo-Youn Cho, Kyung-Sang Yu, In-Jin Jang, SeungHwan Lee
Summary: This study compared the pharmacokinetic properties and tolerability of ranolazine between healthy Korean and white subjects. Results showed that while ranolazine exposure was similar between Korean and white subjects in all dose groups, Korean subjects had a higher exposure at 750 mg compared to white subjects, with an increase of up to 29%.
CLINICAL THERAPEUTICS
(2021)
Article
Medicine, General & Internal
Francesco Radico, Augusto Di Castelnuovo, Alberto Aimo, Marco Zimarino, Juhani Knuuti, Serena Rossi, Luigi Emilio Pastormerlo, Luc Zyw, Enrico Orsini, Licia Iacoviello, Danilo Neglia, Michele Emdin, Giovanni de Gaetano, Raffaele De Caterina
Summary: The prognosis of angina patients without obstructive coronary artery disease (CAD) is heterogeneous, with non-obstructive CAD and myocardial ischemia at imaging tests both conferring a higher risk of cardiovascular events.
JOURNAL OF INTERNAL MEDICINE
(2022)
Review
Pharmacology & Pharmacy
Lavanya Ayyasamy, Bhavani Shankara Bagepally
Summary: This study aimed to evaluate the cost-effectiveness of Ranolazine for the treatment of stable angina pectoris. The findings from the systematic review and meta-analysis suggest that add-on Ranolazine therapy is cost-effective for chronic stable angina pectoris up to a 1-year time horizon.
CLINICAL THERAPEUTICS
(2023)
Article
Cardiac & Cardiovascular Systems
Juan Carlos Kaski, Nuria Lluch, Jose-Luis Lopez-Sendon, Diana A. Gorog, Isabel Antorrena-Miranda, Pablo Avanzas, Pablo Herrero Puente, Alessandro Sionis, Jose R. Gonzalez-Juanatey, Andres Iniguez, Alberto Cordero, Emmanuel Ako, Francisco Fernandez-Aviles, Felipe Atienza, Alejandro Recio-Mayoral, Alan H. B. Wu, Filippo Crea, Robert Storey, Lina Badimon, Judit Cubedo
Summary: This study suggests that circulating ApoJ-Glyc levels are associated with myocardial ischemia in patients with chest pain in the emergency department, even in the absence of troponin elevations. Therefore, ApoJ-Glyc may be a useful marker of myocardial ischemia in this setting.
INTERNATIONAL JOURNAL OF CARDIOLOGY
(2023)
Review
Peripheral Vascular Disease
Lina Ya'Qoub, Islam Y. Elgendy, Carl J. Pepine
Summary: This article discusses the definition, epidemiology and risk factors, pathophysiology, management, and current knowledge gaps and ongoing clinical trials of patients with ischemia with non-obstructive coronary artery disease (INOCA). Studies have shown that INOCA is associated with increased risk of major adverse cardiac events and significant burden on the health care system. The recent CorMicA trial showed that stratified medical therapy based on the type of INOCA improved patients' symptoms and quality of life.
CURRENT ATHEROSCLEROSIS REPORTS
(2022)
Article
Cardiac & Cardiovascular Systems
Jun Sugisawa, Yasuharu Matsumoto, Masashi Takeuchi, Akira Suda, Satoshi Tsuchiya, Kazuma Ohyama, Kensuke Nishimiya, Mina Akizuki, Koichi Sato, Shoko Ohura, Hideki Ota, Shohei Ikeda, Tomohiko Shindo, Yoku Kikuchi, Kiyotaka Hao, Takashi Shiroto, Jun Takahashi, Satoshi Miyata, Yasuhiko Sakata, Kei Takase, Masahiro Kohzuki, Hiroaki Shimokawa
Summary: The study suggests that exercise training may be beneficial for improving physical performance in VSA patients, although its impact on myocardial blood flow may be limited.
INTERNATIONAL JOURNAL OF CARDIOLOGY
(2021)
Article
Medicine, Research & Experimental
Reza Rahmani, Ehsan Moradi Farsani, Sima Bahrami
Summary: This study compared the antianginal efficacy of ranolazine and allopurinol for symptomatic patients with a history of angioplasty. Both medications were found to improve symptoms, but had different effects on ST depression, chest pain severity, and the Duke Treadmill Score.
INTERACTIVE JOURNAL OF MEDICAL RESEARCH
(2022)
Review
Cardiac & Cardiovascular Systems
Nathaniel R. Smilowitz, Olga Toleva, Alaide Chieffo, Divaka Perera, Colin Berry
Summary: Coronary microvascular disease (CMD) can lead to myocardial ischemia in various clinical scenarios. Routine testing for CMD is supported in patients with ischemia and nonobstructive coronary artery disease. Invasive testing using Doppler or thermodilution measures can determine coronary flow reserve and microvascular resistance. Comprehensive testing can improve symptoms, quality of life, and patient satisfaction by establishing a diagnosis and guiding targeted medical therapy and lifestyle changes. CMD testing may also be useful in other cardiovascular conditions such as acute myocardial infarction, angina after coronary revascularization, heart failure with preserved ejection fraction, Takotsubo syndrome, and after heart transplantation. Educating healthcare providers about CMD is crucial for improving patient-centered outcomes in ischemic heart disease.
CIRCULATION-CARDIOVASCULAR INTERVENTIONS
(2023)
Article
Cardiac & Cardiovascular Systems
Shubh Patel, Marinda Fung, Zhiying Liang, Sonia Butalia, Todd J. Anderson
Summary: This study retrospectively analyzed patients with chest pain syndrome who underwent coronary angiography in Alberta from 1995 to 2020. It found that the prevalence of patients diagnosed with angina with no obstructive coronary artery disease (ANOCA) remained stable over time, indicating the need for further recognition and diagnosis of this condition.
CANADIAN JOURNAL OF CARDIOLOGY
(2023)
